TRANSACTIONS GRANTED EARLY TERMINATION—11/26/2008

<table>
<thead>
<tr>
<th>Trans No.</th>
<th>Acquiring Entities</th>
<th>Acquired Entities</th>
<th>Entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>20090125</td>
<td>Lloyds TSB Group plc</td>
<td>HBOS plc</td>
<td>HBOS plc</td>
</tr>
<tr>
<td>20090132</td>
<td>Affymetrix, Inc</td>
<td>Panomics, Inc</td>
<td>Panomics, Inc</td>
</tr>
</tbody>
</table>

TRANSACTIONS GRANTED EARLY TERMINATION—11/28/2008

<table>
<thead>
<tr>
<th>Trans No.</th>
<th>Acquiring Entities</th>
<th>Acquired Entities</th>
<th>Entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>20090135</td>
<td>Green Equity Investors Side V, L.P</td>
<td>Whole Foods Market, Inc</td>
<td>Whole Foods Market, Inc</td>
</tr>
<tr>
<td>20090136</td>
<td>Green Equity Investors V, L.P</td>
<td>Whole Foods Market, Inc</td>
<td>Whole Foods Market, Inc</td>
</tr>
</tbody>
</table>

FOR FURTHER INFORMATION CONTACT:
Sandra M. Peay, Contact Representative; or Renee Hallman, Contact Representative, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room H–303, Washington, DC 20580, (202) 326–3100.

By Direction of the Commission.

Donald S. Clark,
Secretary.

[FR Doc. E8–29119 Filed 12–9–08; 8:45 am]
BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institute for Occupational Safety and Health; Decision To Evaluate a Petition To Designate a Class of Employees at the Mallinckrodt Chemical Co., Destrehan Street Plant in St. Louis, MO, To Be Included in the Special Exposure Cohort

AGENCY: National Institute for Occupational Safety and Health (NIOSH), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) gives notice as required by 42 CFR 83.12(e) of a decision to evaluate a petition to designate a class of employees at the Mallinckrodt Chemical Co., Destrehan Street Plant in St. Louis, Missouri, to be included in the Special Exposure Cohort under the Energy Employees Occupational Illness Compensation Program Act of 2000. The initial proposed definition for the class being evaluated, subject to revision as warranted by the evaluation, is as follows:

Facility: Mallinckrodt Chemical Co., Destrehan Street Plant.
Location: St. Louis, Missouri.
Job Titles and/or Job Duties: All employees who worked with uranium.

FOR FURTHER INFORMATION CONTACT:
Larry Elliott, Director, Office of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 4676 Columbia Parkway, MS C–46, Cincinnati, OH 45226, Telephone 513–533–6800 (this is not a toll-free number). Information requests can also be submitted by e-mail to OCAS@CDC.GOV.

Dated: December 4, 2008.

Christine M. Branche,
Acting Director, National Institute for Occupational Safety and Health.

[FR Doc. E8–29247 Filed 12–9–08; 8:45 am]
BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institute for Occupational Safety and Health; Decision To Evaluate a Petition To Designate a Class of Employees at the Metallurgical Laboratory in Chicago, Illinois, To Be Included in the Special Exposure Cohort

AGENCY: National Institute for Occupational Safety and Health (NIOSH), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) gives notice as required by 42 CFR 83.12(e) of a decision to evaluate a petition to designate a class of employees at the Metallurgical Laboratory in Chicago, Illinois, to be included in the Special Exposure Cohort under the Energy Employees Occupational Illness Compensation Program Act of 2000. The initial proposed definition for the class being evaluated, subject to revision as warranted by the evaluation, is as follows:

Facility: Metallurgical Laboratory.
Location: Chicago, Illinois.
Job Titles and/or Job Duties: All Atomic Weapons Employer employees.

FOR FURTHER INFORMATION CONTACT:
Larry Elliott, Director, Office of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 4676 Columbia Parkway, MS C–46, Cincinnati, OH 45226, Telephone 513–533–6800 (this is not a toll-free number). Information requests can also be submitted by e-mail to OCAS@CDC.GOV.

Dated: December 4, 2008.

Christine M. Branche,
Acting Director, National Institute for Occupational Safety and Health.

[FR Doc. E8–29245 Filed 12–9–08; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institute for Occupational Safety and Health

Final Effect of Designation of a Class of Employees for Addition to the Special Exposure Cohort

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) gives notice as required by 42 CFR 83.12(e) of a decision to evaluate a petition to designate a class of employees at the Vitro Manufacturing in Canonsburg, Pennsylvania, to be included in the Special Exposure Cohort under the Energy Employees Occupational Illness Compensation Program Act of 2000. The final proposed definition for the class being evaluated, subject to revision as warranted by the evaluation, is as follows:

Location: Vitro Manufacturing.

Job Titles and/or Job Duties: All Atomic Weapons Employer employees.


FOR FURTHER INFORMATION CONTACT: Larry Elliott, Director, Office of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 4676 Columbia Parkway, MS C–46, Cincinnati, OH 45226, Telephone 513–533–6800 (this is not a toll-free number). Information requests can also be submitted by e-mail to OCAS@CDC.GOV.

Dated: December 4, 2008.

Christine M. Branche,
Acting Director, National Institute for Occupational Safety and Health.

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case:

Homer D. Venters, Jr., M.D., University of Illinois at Urbana-Champaign: Based on the report of an investigation conducted by the University of Illinois at Urbana-Champaign (UIUC) and extensive additional image analysis conducted by the Office of Research Integrity (ORI), the U.S. Public Health Service (PHS) found that Dr. Homer D. Venters, former graduate student, Neuroscience Program, UIUC, engaged in scientific misconduct in research supported by National Institute of Mental Health (NIMH), National Institutes of Health (NIH), awards R01 MH051569 and F30 MH12558 and National Institute on Aging (NIA), NIH, award R01 AG06246.

Specifically, PHS found that the Respondent committed misconduct in science:

• By intentionally and knowingly preparing and including duplicate image data in Figures 3 and 10 of PHS fellowship application F31 MH12558, “Neurodegeneration via TNF-alpha inhibition of IGF–1,” submitted in 1999, which was funded as F30 MH12558 from June 1, 2000, to May 31, 2003. Because the duplicate data were labeled as having been obtained from different experiments, the results for at least one of the two figures were intentionally falsified and constitute an act of scientific misconduct.

• By intentionally and knowingly preparing and including duplicate image data in Figure 3 and/or 4 of a manuscript submitted and published as: Venters, H.D., et al. “A New Mechanism of Neurodegeneration: A Proinflammatory Cytokine Inhibits Receptor Signaling by a Survival Peptide.” Proceedings of the National Academy of Sciences U.S.A. 96:9879–9884, 1999.

• By preparing and providing to his dissertation committee in March 2000 a thesis proposal entitled “An Alternate Mechanism of Neurodegeneration: Silencing of Insulin-like Growth Factor I Survival signals by Tumor Necrosis Factor-a,” which contained five falsified figures: Figures 1.3, 1.4a, 2.1b, 2.3e, and 2.5b. In each figure, he reused data within the same figure or in another thesis proposal figure as representing differently treated samples or as data obtained with different immunoblotting antisera.

• In March and April 2001, Respondent included several of the same falsified figures as in the thesis proposal and multiple additional falsified figures in his dissertation “Silencing of Insulin-like Growth Factor I Neuronal Survival Signals by Tumor Necrosis Factor-a.” In all, Figures 3.3, 3.4a, 3.4b, 4.1b, 4.3a, 4.5b, 5.1a, 5.2, 5.4a, 5.5a, 5.6a, 5.7a, and 5.8a were falsified. In each instance, he assembled figures by reusing significant data, on some occasions after manipulating the orientation of the data, either within the same figure or in other figures related to his thesis and represented the data falsely as coming from different samples of different experiments.

Dr. Venters has entered into a Voluntary Settlement Agreement.